KR20150134318A - Composition of novel interleukin-33 receptor and binding protein, and use thereof - Google Patents

Abstract

The present invention relates to novel interleukin-33 receptor and binding protein compositions and uses thereof, and the invention will assist in investigating broad spectrum IL-33 activity in host defense against pathogens and inflammatory diseases.

Description

TECHNICAL FIELD The present invention relates to a novel interleukin-33 receptor and a binding protein composition, and a composition therefor. BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a novel interleukin-

The present invention relates to novel interleukin-33 receptor and binding protein compositions and uses thereof, and the invention will assist in investigating broad spectrum IL-33 activity in host defense against pathogens and inflammatory diseases.

Interleukin (IL) -33 has been identified as a nuclear factor derived from the high endothelial venules as one of the IL-1 cytokine family (Baekkevold, ES, et al. Am IL-33 is a precursor IL-33 molecule that is synthesized and located predominantly in the cell. The precursor IL-33 does not have secreted signal peptides; it is a mature protein that is extracellularly Is secreted.

Highly constant expression of IL-33 along the vasculature is detected in normal tissues and secreted from necrotic cells. This result suggests a possible role for IL-33, similar to HMGB1, as an endogenous 'danger' signal to the immune system after endothelial or epithelial cell damage during trauma or infection (Moussion, C., Ortega, N. & Girard, JP PLoS One 3, e3331 (2008)). Functional studies also indicate that IL-33 is an impairment-associated molecular pattern (DAMP) or alarmins secreted from necrotic cells that respond to prototypic RNA / DNA virus replication in mice. The characteristic biological activity of mature IL-33 has to be addressed.

(Bergers, G., Reikerstorfer, A., Braselmann, S., Graninger, P. & Busslinger, M (1989); Tominaga, S. FEBS letters 258, 301-304 (1994); Klemenz, R., Hoffmann, S. & Werenskiold, AK Proc Natl Acad Sci USA 86, 5708-5712 (1989)) is the ligand binding partner of the IL-33 receptor (Schmitz, J., et al. Immunity 23, 479-490 (2005)). The IL-33 receptor complex for signal transduction is composed of the ligand binding ST2 (IL-1R4) and the signal transduction IL-1 receptor subfamily (IL-1RAcP; IL-1R3). After IL-33 binding, the receptor complex is capable of expressing downstream signaling molecules such as NF-kB and AP-1 through IRAK (IL-1 receptor-associated kinase), TRAF6 (TNF receptor associated factor 6) and / Activate. ST2 is a selective marker for Th2 cells in mouse and human (Trajkovic, V., Sweet, MJ & Xu, D. Cytokine Growth Factor Rev 15, 87-95 (2004); Lohning, M., et al., Proc Natl Acad Eosinophils, and even basophils, in the presence of a variety of other cytokines, such as cytokines, cytokines, and cytokines. These cells produce Th2 inflammatory cytokines and chemokines including IL-4, IL-5, IL-6, IL-13 and IL-8 by stimulation of IL-33. Circulating CD34 + hematopoietic progenitor cells express ST2 and secrete high levels of Th2-related cytokines and respond to IL-33.

SUMMARY OF THE INVENTION The present invention has been made in view of the above needs, and an object of the present invention is to identify a novel interleukin (IL) -33 receptor.

Another object of the present invention is to provide a novel composition for preventing or treating autoimmune diseases.

In order to achieve the above object, the present invention provides a receptor and an antibody against interleukin (IL) -33, which comprises IL-1 receptor accessory protein 2 (IL-1R9) and IL-18 binding protein Protein composition.

In one embodiment of the present invention, the IL-1 receptor subtype 2 (IL-1R9) is preferably composed of one of the amino acid sequences set forth in SEQ ID NOS: 1 to 2, but is not limited thereto.

In another embodiment of the present invention, the IL-18 binding protein (IL-18BP) preferably comprises one of the amino acid sequences set forth in SEQ ID NOS: 3 to 6, but is not limited thereto.

In another embodiment of the present invention, the interleukin (IL) -33 is preferably composed of the amino acid sequence of SEQ ID NO: 7 (precursor IL-33) or 8 (Mature IL-33), but is not limited thereto.

The present invention also relates to an IL-33-related autoimmune (IL-1R) -related autoimmune disease comprising as an active ingredient at least one protein selected from the group consisting of IL-1 receptor subtype 2 (IL-1R9) and IL- A composition for preventing and treating diseases is provided.

In one embodiment of the invention, the autoimmune disease is selected from the group consisting of rheumatoid arthritis, osteoarthritis, chronic arthritis of childhood, Lyme arthritis, psoriatic arthritis, reactive arthritis and septic arthritis, spondyloarthritis, systemic lupus erythematosus, Acute or chronic immunodeficiency associated with organs transplantation, sarcoidosis, atherosclerosis, inflammatory bowel disease, inflammatory bowel disease, insulin dependent diabetes mellitus, thyroiditis, asthma, allergic disease, psoriasis, dermatitis skin sclerosis, graft versus host disease, , Henoch-Schonlein purpurea, microscopic vasculitis of the kidney, chronic active hepatitis, uveitis, septic shock, rheumatoid arthritis, rheumatoid arthritis, rheumatoid arthritis, Toxic shock syndrome, sepsis syndrome, cachexia, infectious disease, parasitic disease, acquired immunodeficiency syndrome, acute transverse myelitis, Huntington's chorea, Parkinson's disease, Myocardial infarction, Addison's disease, sporadic, multiple myeloid deficiency type I and multifactorial deficiency type II, Schmidt's syndrome, adult (acute) dyspnea, seizures, seizures, first-degree inertial cirrhosis, hemolytic anemia, malignant cancer, heart failure, myocardial infarction, Syndrome, alopecia, alopecia areata, felicitous serum arthropathy, arthritis, lighter sickness, psoriatic arthropathy, ulcerative jurisitis arthropathy, bowel disease synovitis, chlamydia, yersinia and salmonella related arthropathy, spondyloarthropathies, porcine atherosclerosis, atopic Primary allergic disease, autoimmune waterborne disease, common pemphigus, pemphigus pemphigus, pemphigus, primary IgA disease, autoimmune hemolytic anemia, coccus positive hemolytic anemia, acquired aplastic anemia, childhood anemia, myalgic encephalitis, Royal Free Disease ), Chronic mucocutaneous candidiasis, giant cell arteritis, primary sclerosis hepatitis, latent autoimmune hepatitis, acquired immunodeficiency syndrome, acquired immunodeficiency disease, hepatitis B, hepatitis C, common variability (Such as chronic obstructive pulmonary disease, chronic obstructive pulmonary disease, chronic obstructive pulmonary disease, chronic obstructive pulmonary disease, chronic obstructive pulmonary disease, chronic obstructive pulmonary disease, Chronic obstructive pulmonary disease, systemic lupus-related pulmonary disease, skin mucositis / multiple myalgia-related pulmonary disease, Sjogren's disease-related pulmonary disease, ankylosing spondylitis-related pulmonary disease, vasculitis Chronic obstructive pulmonary disease, chronic eosinophilic pneumonia, lymphocytic infiltration lung disease, interstitial lung disease, gouty arthritis, autoimmune hepatitis, type 1 autoimmune hepatitis (including chronic obstructive pulmonary disease, chronic obstructive pulmonary disease, Classical autoimmune or lupus hepatitis), type 2 autoimmune hepatitis (anti-LKM antibody hepatitis), autoimmune mediated hypoglycemia, , Hypoparathyroidism, acute immune diseases related to organ transplantation, chronic immune diseases related to organ transplantation, osteoarthritis, primary sclerosing cholangitis, psoriasis type 1, psoriasis type 2, papillary leukopenia, autoimmune neutropenia, kidney disease NOS, glomerulonephritis, kidney (All subtypes), sympathetic eye inflammation, pulmonary hypertension secondary to connective tissue disease, Goodpasture's syndrome, nodular polyarteritis nodosa (Nodular polyarteritis nodosa) Atherosclerosis, autoimmune thrombocythemia, autoimmune thrombocythemia, autoimmune thyroid disease, hypothyroidism, hypothyroidism, autoimmune thyroid autoimmune disease, autoimmune thyroid disease, autoimmune thyroid disease, Hypothyroidism (Hashimoto's disease), atrophic autoimmune hypothyroidism, primary mucinous edema, hydroentangitis, primary vasculitis, vitiligo, grade Induced hepatitis, nonalcoholic fatty liver disease, allergy and asthma, Group B streptococcus (GBS) infection, mental illness, Th2 type, hepatocellular carcinoma, And Th1 type mediated diseases, acute and chronic pain, and cancer.

The present invention also relates to the use of an antibody against at least one protein selected from the group consisting of IL-1 receptor accessory protein 2 (IL-1R9) and IL-18 binding protein (IL-18BP) ≪ / RTI >

The antibodies of the present invention can be prepared by any of a variety of techniques known in the art. Particularly preferred methods of producing antibodies of the invention include methods using XENOMOUSE gene transfer mice, hybridoma and SLAM cell transplantation techniques (Abgenix, Inc., Fremont, CA) known in the art for preparing antibodies Method.

The present invention also provides a pharmaceutical composition comprising the protein of the present invention and an antibody or antigen-binding portion thereof and a pharmaceutically acceptable carrier. In one embodiment, the pharmaceutical composition further comprises one or more further therapeutic agents for the treatment of diseases which are detrimental to IL-33 activity.

Some of the antibodies and antibodies of the invention may be incorporated into pharmaceutical compositions suitable for administration to a subject. In general, the pharmaceutical compositions comprise an antibody or antibody portion of the invention and a pharmaceutically acceptable carrier. The term "pharmaceutically acceptable carrier " as used herein includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, which are physiologically compatible. Examples of pharmaceutically acceptable carriers include water, saline, phosphate buffered saline, dextrose, glycerol, ethanol, and the like, or a combination thereof. In most cases it is preferred that the composition comprises an isotonic agent, a polyalcohol such as mannitol, sorbitol or sodium chloride. The pharmaceutically acceptable carrier may further comprise minor amounts of wetting or emulsifying agents, preservatives or buffers, which enhance the useful life or effectiveness of the antibody or portion of the antibody.

Some of the antibodies and antibodies of the invention may be incorporated into pharmaceutical compositions suitable for parenteral administration. Here, the antibody or a part of the antibody is preferably prepared with an injection solution containing 0.1 to 250 mg / ml of antibody. The injection solution may be in the form of a liquid or lyophilized dosage form in a flint or amber bayer, ampoule or prefilled syringe. The buffer may be L-histidine (1-50 mM) at pH 5.0-7.0 (optimally pH 6.0), optimally 5-10 mM. Other suitable buffers include, but are not limited to, sodium succinate, sodium citrate, sodium phosphate or potassium phosphate. Sodium chloride may be used to modify the toxicity of the solution at a concentration of 0-300 mM (optimally 150 mM for liquid dosage forms). In the lyophilized dosage form, a cryoprotectant, predominantly 0 to 10% sucrose (optimally 0.5 to 1.0%) may be added. Other suitable cryoprotectants include trehalose and lactose.

In the lyophilized dosage form, the intestinal expandable drug, mainly 1 to 10% mannitol (optimally 2 to 4%) may be added. In the form of liquid and freeze-dried dosage forms, stabilizers, mainly 1 to 50 mM L-methionine (optimally 5 to 10 mM) may be added. Other suitable

The intestinal expandable drugs include glycine and arginine, which may be included as 0 to 0.05% polysorbate-80 (optimally 0.005 to 0.01%). Other surfactants include, but are not limited to, polysorbate 20 and BRIJ surfactants.

The compositions of the present invention may be in various forms. Such forms include, for example, liquid, semi-solid and solid dosage forms such as liquid solutions (e.g., injection and infusion solutions), dispersions or suspensions, tablets, pills, powders, liposomes and suppositories. The preferred form differs according to the intended mode of administration and therapeutic use. A generally preferred composition is a composition similar to that used for passive immunization of humans with injection solutions or injection solutions, such as other antibodies. The preferred mode of administration is parenteral (e. G., Intravenous, subcutaneous, intraperitoneal, intramuscular) administration. In a preferred embodiment, the antibody is administered by intravenous infusion or injection. In another preferred embodiment, the antibody is administered intramuscularly or subcutaneously.

Therapeutic compositions can generally be sterilized and stable under the conditions of manufacture and storage. Such compositions may be formulated as solutions, microemulsions, dispersions, liposomes or other custom structures suitable for high drug concentrations. Sterile injectable solutions can be prepared by mixing the required amount of the active compound (i. E., Antibody or antibody portion), optionally in combination with one or a combination of ingredients listed above, in a suitable solvent, followed by filter sterilization. Generally, dispersions are prepared by adding the active compound to a sterilizing medium comprising a basic dispersion medium and, if desired, the other ingredients described above. In the case of sterile lyophilized powders useful for the production of sterile injectable solutions, the preferred method of preparation is vacuum drying and spray drying, which provide powders of the active ingredient and any desired additional ingredients from the sterile filtration solution described above. The proper fluidity of the solution can be maintained, for example, through the use of a coating such as lecithin, the maintenance of the required particle size in the case of dispersions, and the use of surfactants. Continuous absorption of the injection composition can be provided by adding an absorption delaying agent, such as monostearate salt and gelatin, to the composition.

Some of the antibodies and antibodies of the invention can be administered in a variety of ways known in the art, but the preferred route / mode of administration for various therapeutic applications is subcutaneous injection, intravenous injection or infusion. As will be appreciated by those skilled in the art, the route and / or route of administration will depend on the desired result. In certain embodiments, the active compound may be formulated with a carrier that does not release the compound rapidly, examples of which include controlled release formulations including implants, transdermal patches, and microencapsulated delivery systems. Biodegradable, biodegradable polymers such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters and polylactic acid may be used herein. Many methods of making such formulations are patented or generally known to those skilled in the art

(E.g., Sustained and Controlled Release Drug Delivery Systems, J. R. Robinson, ed., Marcel Dekker, Inc., New York, 1978).

In certain embodiments, an antibody or a portion of an antibody of the invention may be orally administered, for example, with an inert diluent or a culture-compatible edible carrier. These compounds (and other components if desired) may also be packed in hard or soft shell gelatin capsules, squeezed into tablets, or added directly to the subject's diet. For oral therapeutic administration, the compound may be formulated with ingestible tablets, buccal tablets, troches, capsules; Elixirs, suspensions, syrups, wafers, and the like. In order to administer the compounds of the present invention in a manner other than parenteral administration, it may be necessary to co-administer the compounds with an anti-inactivation agent or co-administer with the inhibitory agent.

A pharmaceutical composition of the invention may comprise a "therapeutically effective amount" or "prophylactically effective amount" of an antibody or a portion of an antibody of the invention. The term " therapeutically effective amount "means an amount effective to achieve the desired therapeutic result and an effective amount for a required period of time.

The therapeutically effective amount of the antibody or antibody portion may vary depending on factors such as disease state, age, sex and body weight and the ability of the antibody or portion of the antibody to elicit the desired response in the subject . In addition, a therapeutically effective amount is one in which the therapeutic benefit benefits outweigh any toxic or deleterious effects of the antibody or antibody portion. By "prophylactically effective amount" is meant an amount effective to achieve the desired prophylactic result and an effective amount for the required period of time. In general, the prophylactic dose will be less than the therapeutically effective dose, since the prophylactic dose will be used in the subject before or at an early stage of the disease.

The dosage regimen may be adjusted to provide the desired optimal response (e. G., Therapeutic or prophylactic response). For example, one bolus may be administered, several divided doses may be administered over time, or a proportionally reduced or increased dose may be administered depending on the severity of the treatment situation. In particular, it is advantageous to prepare parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suitable as unitary dosages for the mammalian subjects to be treated. Thus, each unit comprises a predetermined amount of the active compound calculated to provide the desired therapeutic effect in association with the required pharmaceutical carrier. The details of the dosage unit form of the present invention are not limited to the specific types of active compounds and the particular therapeutic or prophylactic effect to be obtained, and (b) the specificity of the compound It is determined according to restrictions and is directly influenced.

An exemplary range of non limit for a therapeutically or prophylactically effective amount of an antibody or antibody portion of the invention is 0.1 to 20 mg / kg, more preferably 1 to 10 mg / kg. Dosage values may also be adjusted to suit the needs of the individual and the expertise of the person administering or supervising the administration of the composition

The dosage ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed compositions.

Hereinafter, the present invention will be described in detail.

(IL-18BPa) of IL-18BP, IL-18BPa Fc (IL-18BPa-Fc) and IL-18BPa of SEQ ID NOS: 1 to 2 and IL-1R9- (IL-18BPc) and IL-18BPc (IL-18BPc-Fc), respectively.

Since IL-33 interacts with IL-18BP and IL-1R9 through IL-33, IL-33 regulates both Th1 and Th2 cytokines and thus can be used for Th1 and Th2-related autoimmune diseases.

More specifically, IL-18BP is used for both Th1 (rheumatoid arthritis, colitis, psoriasis) and Th2 (Asthma and atopic dermatitis). For this reason, IL-33, when acting alone, induces a Th2 immune response if it cooperates with IL-12, IL-2 and IFN alpha.

To date, the report of IL-18BP focuses only on IFN-gamma inhibition induced by IL-18 and has been registered as a therapeutic agent for Th1 immunosuppression, and the inventors of the present invention have been involved.

In addition, in the case of IL-1R9, it has been known that the ligand of orphan receptor does not exist in the result of the present invention. However, IL-33 is a ligand of IL-1R9 and Fc-IL-1R9 does not directly bind IL-33 co-receptor and play an important role in the Th1 immune response induced by IL-33, that is, induction of IFN gamma.

Thus, neutralizing antibodies that inhibit the function of IL-1R9 may be prepared and used to specifically and selectively inhibit the Th1 immune response of IL-33.

The Th1-related autoimmune disease may also be selected from the group consisting of autoimmune hepatitis, chronic rheumatoid arthritis, insulin dependent diabetes mellitus, ulcerative colitis, Crohn's disease, multiple sclerosis, autoimmune myocarditis, psoriasis, scleroderma, (Hashimoto ' s disease, autoimmune cytopenias (e.g., erythrocyte anemia, aplastic anemia, etc.), Sjogren's syndrome, vasculitis syndrome, systemic lupus erythematosus,

The Th2-related autoimmune diseases include allergic asthma, allergic rhinitis, seasonal allergic rhinitis, atopic dermatitis, contact hypersensitivity (including contact dermatitis), conjunctivitis, especially allergic conjunctivitis, eosinophilic bronchitis, food allergy, Autoimmune diseases such as inflammatory bowel disease, ulcerative colitis, Crohn's disease, mastocytosis and hyper IgE syndrome and systemic lupus erythematosus, psoriasis, acne, multiple sclerosis, transplant rejection, reperfusion injury, chronic obstructive lung Diseases, rheumatoid arthritis, psoriatic arthritis and osteoarthritis, and the like.

The present inventors have attempted to identify a putative interleukin (IL) -33 receptor. IL-33 affinity chromatography separated the novel IL-33 interacting protein IL-1R9 (IL-1 receptor accessory protein 2 (IL-1RAcPL2; IL-1R9) and IL-18BP IL-18 interacts with IL-18BP rather than IL-1R9. Interestingly, IL-18BP inhibits IFNγ and IL-8, while anti-IL-1R9 selectively inhibits IFNγ. , mature IL-33 induces IFNγ, but precursor IL-33 fails to induce IFNγ This result will help investigate a broad spectrum of IL-33 activity in host defense against pathogens and inflammatory diseases. IL-1R9 < / RTI > (IL-1RAcPL2) and IL-18BP, which are novel IL-33 receptor related molecules, are selectively involved in the biological activity of IL-33 in various cell types.

On the other hand, IL-1R4 and IL-1R3 are expressed in HMC-1 cells whereas human PBMCs express IL-1R4 and IL-1R9, which contribute to IFNγ production. This result was demonstrated with an anti-IL-1R9 antibody that specifically neutralizes IL-33-induced IFN gamma in human PBMC. Water soluble IL-18BP and IL-1R4 specifically bound to IL-33 (Fig. 2) and inhibited IL-33-induced cytokines.

In addition, anti-IL-1R9 was not able to inhibit IL-8 induction in HMC-1 cells (Fig. 5a), but specifically inhibited IL-33-induced IFNγ in PBMC (Fig. This result suggests a unique conformation of the IL-33 receptor in other cell types. In other words, the IL-33 receptor is composed of IL-1R4 and IL-1R3 in HMC-1 cells and the IL-33 receptor is composed of IL-1R4 and IL-1R9 in PBMC The -33 receptor IL-IR3 or IL-lR9 has binding affinity to the ligand after IL-33 / IL-lR4 precomplex formation (Fig. 5C). Events of the IL-33 / receptor complex on the cell membrane leading to downstream cytokines are blocked by soluble IL-33 receptors and binding proteins (Figure 5c, right panel)

Induction of IFNγ by IL-33 in the presence of several costimulatory factors was sufficiently inhibited by two IL-33 inhibitors combined, such as FcIL-1R4 and FcIL-18BPa (FIG. 8).

We investigated whether IL-33-induced IFNy is inhibited by IL-10. IFN gamma producing cell lines were markedly increased in both human PBMC and mouse splenocyte / lymph node cells (Fig. 7). The synergistic effect of IL-12-induced IFN gamma producing cell lines was more effective than that of LPS.

The results of the present invention will be an important experimental tool for analyzing the precise role of IL-33 in the immune response.

Hereinafter, the present invention will be described in detail.

IL-33 ligand-affinity chromatography separates IL-1R9 and IL-18BP

Novick, D., et al. Mature recombinant IL-33 protein (5 mg) was produced to prepare IL-33 ligand-affinity chromatography as described in Immunity 10, 127-136 (1999). Concentrated human urine was applied to the IL-33 ligand-affinity column to isolate the water-soluble IL-33 binding protein. After washing, the acid solution-eluted IL-33 binding protein was examined by Western blot. Prior to western blotting, the present inventors have found that IL-1R9 (IL-1RAcPL2) has been used to select candidate receptors resulting in having a high homology (35.3% identity) with IL-1R3 The homologues of the IL-33 receptor were analyzed by comparison. Thus, we performed western blot with anti-IL-1R9 antibody. The band with a molecular weight of approximately 53 kDa was recognized by the anti-human IL-1R9 antibody but not in the control lane (Fig. 1A). Biological activity of IL-33 was significantly higher than that of both IL-18-induced Th1 / Th2 cytokines The similar fractions derived from ligand-affinity chromatography were used to test IL-18BP. A predicted molecular weight of IL-18BP of about 40 kDa was specifically detected with anti-IL-18BP antibody (Fig. 1b). A similar experiment was performed to confirm that the fractions eluted from the affinity chromatography were of known IL- Respectively. The predicted molecular mass of urine-soluble IL-1R3 (IL-1RAcP) and IL-1R4 (ST2) were detected (Figure 1c / d) and the results were consistent with previous reports (Smith, DE, et al. Immunity 18, 87 -96 (2003); Yanagisawa, K., et al J Biochem 121, 95-103 (1997)).

Analysis of specific interactions between IL-1 ligand and receptor / binding protein

To analyze specific interactions between IL-1 ligands and receptors, the inventors of the present invention have reported that Hong, K., et al. Human IL-1R9, IL-18BPa, IL-18BPc, and IL-1R4 were expressed as Fc fusion proteins as described in Hybridoma (Larchmt) 31, 99-104 (2012). Recombinant FcIL-1R9 was purified by Protein A affinity chromatography using serum-free medium from an FcIL-1R9 CHO stable clone, but FcIL-1R9 failed to interact with IL-33, Suggesting that IL-1R9 may act as a signaling chain because it does not possess binding affinity for the ligand by itself in the second chain. We performed immunoprecipitation assays with FcIL-18BPa and c to clarify the results of FIG. 1b. Both FcIL-18BPa and c interacted specifically with mature IL-33 (Fig. 2A), but only FcIL-18BPa had a binding affinity to precursor IL-33 (Fig. 2B). It is interesting to investigate whether FcIL-1R4 interacts with IL-18 because IL-18BP binds to IL-33, but FcIL-1R4 fails to interact with mature (Figure 2c) and precursor IL-18 (Fig. 2d). Immunoprecipitation assays were repeated to demonstrate the interaction of IL-33 with FcIL-1R4. FcIL-1R4 specifically interacted with mature IL-33 (Figure 2e) but not with precursor IL-33 (Figure 2f).

IL-18BP isoform selectively inhibits IL-33 activity

To investigate the unique interaction of IL-18BPa with the precursor IL-33, the present inventors tested whether IL-18BPa inhibits precursor IL-33-induced IL-8 production in HMC-1 cells. IL-8-induced IL-8 was inhibited by FcIL-18BPa in human HMC-1 cells (Fig. 3a) but IL-8 inhibition was not obtained by FcIL-18BPc (Fig. 3b). Both FcIL-18BPa and c inhibit mature IL-33- induced IL-8 in a sufficiently dose-dependent manner (Fig. 3c / d). Inhibition of IL-33- induced IL-8 production by FcIL-18BPa Since both FcIL-1R4 and FcIL-18BP interact with mature IL-33, the present inventors have found that the combination of mature IL-33-induced IL-8 production in HMC- FcIL-1R4 + FcIL-18BPa or FcIL-1R4 + FcIL-18BPc. IL-8 was effectively inhibited by the combined inhibitors and the dose response of the combined inhibitors was more linear than IL-18BP alone / f).

Characteristic biological activity of mature IL-33 in IFNγ induction

As shown in FIG. 3, IL-8 production stimulated with precursor IL-33 (100 ng / ml) in HMC-1 cells showed that the biological activity of the precursor IL-33 was 10 / 20-fold less activity. We investigated precursors and mature IL-33-induced IFNy in the presence of IL-12. Human peripheral blood mononuclear cells (PBMC) and mouse spleen cells were stimulated with precursor and mature IL-33 in the presence of IL-12. Unlike the results of FIG. 3a / b, only mature IL-33 + IL-12 induced synergistically IFN gamma while very high concentrations (1 mg / ml) of precursor IL-33 also failed to induce IFN gamma b).

IL-1R9 is a component of the IL-33 receptor in PBMC but not in HMC-1 cells

IL-33 ligand affinity chromatography separated the rare receptor IL-1R9 (IL-1RAcPL2) (Fig. 1A), but recombinant FcIL-1R9 failed to interact with both the precursor and mature IL- 1R9 acts as a signaling chain with no direct binding affinity to the ligand. Therefore, the present inventors conducted an IL-33 assay with anti-IL-1R9 and FcIL-1R4 to understand how IL-1R9 participates in IL-33 biological activity. Mature IL-33 significantly increased IL-8 production in human HMC-1 (Fig. 5A). The induction of IL-8 was specifically inhibited by FcIL-1R4, but anti-IL-1R9 and control anti-IL-1R8 did not inhibit IL-33 activity (FIG. Next, we performed IL-33 assays with human PBMCs producing IFNy in the presence of IL-12. Interestingly, anti-IL-1R9 specifically inhibited IFN gamma production, but did not achieve inhibition with the control anti-IL-1R8 antibody (FIG. 5b). In order to illustrate this data, the differential expression of IL-33 receptor components in HMC-1 and PBMC was depicted (Figure 5c). IL-33 inhibition assay showed that HMC-1 inhibited IL-1R4 (ST2) 1R3 (IL-1RAcP) while PBMCs express IL-1R4 (ST2) and IL-1R9 (IL-1RAcPL2). The IL-33 / IL-1R4 precomplex recruits IL-1R3 in HMC-1 or recruits IL-1R9 in PBMC (Figure 5c, left to right panel). IL- IL-33 inhibitory complexes such as sIL-1R4 are present in the circulatory system and inhibit IL-33 access to their receptors on the cell membrane (Fig. 5c, right panel).

Inhibition of IFNγ by several IL-33 inhibitors

Prior to investigating the inhibitory effects of soluble IL-33 receptors and binding proteins, the inventors investigated the synergistic effect between IL-33 and IL-18. The inventors of the present invention found that IFN gamma with different combinations of IL-12 + IL-18, IL-12 + IL-33, or IL-12 + IL-18 + IL-33 to evaluate possible synergistic effects between IL- Lt; / RTI > IL-18 or IL-33 in the presence of IL-12 elevated IFN [gamma] production, which was further increased by IL-12 + IL-18 + IL-33 stimulation (Fig. 6a). IL-18 plus IL-33 showed additional effects. Inhibition of IFN [gamma] was tested with a combination of single, double or triple inhibitors. FcIL-1R4 as well as FcIL-18BPa and c specifically inhibited IL-18- and IL-33-induced IFN gamma but FcIL-lR4 inhibited IL-18-induced IFN gamma This result was in agreement with the immunoprecipitation assay (Fig. 2c / d). Similar inhibition was obtained with two or three combined inhibitors and the inhibition was significant in FcIL-1R4 in combination with FcIL18BPa or FcIL18BPc (Fig. 6C).

FACS analysis of IFNγ-producing cells by IL-33 stimulation + costimulatory factor

Since LPS is used as a costimulatory factor in IL-18-induced IFN [gamma], IFN [gamma] producing cells were measured in human PBMC and mouse spleen cells after stimulation with IL-12, IL-33, and LPS. IL-4 and IFN [gamma] producing cells were examined by FACS analysis 24 hours after stimulation as shown in Fig. In human PBMC, IL-12 + IL-33 markedly increased the number of IFN gamma producing cells, but IL-4 producing cells were not detected (Figure 7a). -33 + IL-12. ≪ / RTI > The same experiment was repeated with mouse splenocytes (Figure 7b) and lymph node cells (Figure 7c). The results were very similar to human PBMCs. We verified FACS analysis by measuring IFN gamma production in cultured supernatants, and LPS-induced IFNy was less than twice that of IL-12.

In the presence of several costimulatory factors, IL-33-induced IFNγ is destroyed by IL-33 inhibitors

To test the effect of costimulatory factors on IL-33-induced IFN [gamma], human PBMC and mouse splenocytes were treated with mature IL-33 in the presence of various costimuli (Fig. 8a / b). The synergistic effect on IFN [gamma] production was obtained with IL-2, IL-12 and IFNa, but not with TNF [alpha]. IL-12 was the most potent costimulatory factor in human PBMC and mouse spleen cell assays (Figure 8a / b). We investigated the effect of IL-33 inhibitory molecules (FcIL-18BPa + FcIL-1R4) on IL-33-induced IFNγ and this combination was chosen because it provides the greatest inhibition of IFNγ (Figure 3e / f and 6c). The combination of two IL-33 inhibitors selectively inhibited IL-33-induced IFN [gamma] in human PBMC and mouse splenocytes (Fig. 8a / b).

Signal transduction of IL-33 plus IL-12 synergistically increasing IFNγ production

We first examined STAT4 phosphorylation over time and observed STAT4 phosphorylation 36 hours after IL-12 stimulation (Figure 9a, lane 5 in the left panel). Simultaneous treatment of IL-33 further increased STAT4 phosphorylation after 36 hours of stimulation (Figure 9a, lane 4 in the middle panel), but IL-18 concurrent treatment did not increase STAT4 compared to IL-12 alone (Figures 9a, Next, we examined NF-kB phosphorylation and, unlike STAT4, NF-kB fully activated 30 minutes after IL-12 stimulation but phosphorylation of NF-kB disappeared at 4 hours In the panel line 2). Interestingly, co-treatment of IL-33 or IL-18 displaced the maximal activation of NF-kB at 4 hours (Fig. 9a, ine 2 in the middle and right panel) and remained until 36 hours. Similarly, phosphorylation of p38 mitogen-activated protein kinase (p38MAPK) and p44 / 42 mitogen-activated protein kinase (p44 / 42MAPK) was investigated (Fig. 9a, lines 3 and 4). Phosphorylation of p44 / 42MAPK in human PBMC was less noticeable, but p38MAPK was not activated by these stimuli. The signaling effects of FcIL-18BPa, anti-IL-1R9, or FcIL-1R4 and several combinations of these inhibitors were also tested after 4 or 36 hours of stimulation. NF-kB phosphorylation was suppressed by at least two combined inhibitors whereas STAT4 activation increased where FcIL-1R4 was added at the 4 hour stimulus (Fig. 9b, lines 1 and 2). The other two pathways were unaffected (Figure 9b, lines 3 and 4). Ultimately, several inhibitors combined at 36 hours of stimulation markedly destroyed STAT4 and NF-kB phosphorylation including p38MAPK (FIG. 9c, lines 1 and 2), whereas the combined inhibitors were p44 / 42MAPK phosphorylation (Figure 9c, lines 3 and 4).

T-helper (Th) T-cell subtype immunoreactivity is regulated by specific cytokines that regulate unique subset differentiation and proliferation. It is important to understand the regulation of cytokines because disproportionate cytokine production causes multiple immune disorders. The present invention suggests that the merging edge of the Th1 / Th2 immune response is tightly regulated by IL-1 family cytokine and receptor related molecules. The novel IL-33 receptor and binding proteins, including the biological activity of mature IL-33 in the IFN [gamma] production of the present invention, will be useful for investigating important immunomodulation associated with the Th1 / Th2 immune response.

In addition, since IL-33 interacts with IL-18BP and IL-1R9 through IL-33, IL-33 regulates both Th1 and Th2 cytokines and thus can be used for Th1 and Th2-related autoimmune diseases. The Th1-related autoimmune disease is selected from the group consisting of autoimmune hepatitis, chronic rheumatoid arthritis, insulin dependent diabetes mellitus, ulcerative colitis, Crohn's disease, multiple sclerosis, autoimmune myocarditis, psoriasis, scleroderma, It is preferably selected from autoimmune diseases, autoimmune diseases, autoimmune diseases (e. G., Erythrocyte anemia, aplastic anemia), Sjogren's syndrome, vasculitis syndrome and systemic lupus erythematosus,

The Th2-related autoimmune diseases include allergic asthma, allergic rhinitis, seasonal allergic rhinitis, atopic dermatitis, contact hypersensitivity (including contact dermatitis), conjunctivitis, especially allergic conjunctivitis, eosinophilic bronchitis, food allergy, Autoimmune diseases such as inflammatory bowel disease, ulcerative colitis, Crohn's disease, mastocytosis and hyper IgE syndrome and systemic lupus erythematosus, psoriasis, acne, multiple sclerosis, transplant rejection, reperfusion injury, chronic obstructive lung Diseases, rheumatoid arthritis, psoriatic arthritis and osteoarthritis, and the like.

Figure 1 shows the Western blot of a soluble IL-33 binding protein isolated from IL-33 ligand affinity chromatography. Human IL-33 ligand-affinity chromatography separated urine IL-33 interacting protein and detected by Western blot. Four fractions were eluted from the IL-33 ligand affinity column. (a) The anti-IL-1R9 antibody recognizes a water-soluble IL-1R9. A band having a molecular weight of about 53 kDa was detected in the eluted fraction. The theoretical molecular weight of the mature IL-1R9 extracellular domain (340 polypeptide) is 39 kDa. The predicted four N-linked glycosylation sites (the tripeptide sequence Asn-X-Ser or Asn-X-Thr, where X may be an unspecified amino acid) increase the affinity of the urinary IL-1R9. Western blots with specific antibodies recognize urine (b) IL-18BP, (c) IL-1R4 or (d) IL-1R3. Data represent one of three independent experiments.
Figure 2 shows the specific interaction of precursor and mature IL-33 with Fc receptors and binding proteins. (a) Mature or (b) precursor IL-33 was immunoprecipitated with recombinant FcIL-18BPa and c isoform, respectively. Similarly, recombinant FcIL-1R4 was used for immunoprecipitation of (c) Mature IL-18, (d) precursor IL-18, (e) Mature IL-33, or (f) precursor IL-33. Each ligand (100 ng) was mixed with 500 ng of Fc fusion protein in PBS for 30 min on ice. The complex of ligand and Fc fusion protein was precipitated with protein A beads (10 ml). The mixed components are shown at the top. The data represents one of four independent experiments.
Figure 3 shows inhibition of precursor or mature IL-33-induced IL-18 in HMC-1 cells. The induction of IL-8 production by precursor IL-33 (a and b) was dose-dependently inhibited by FcIL-18BPa but not by FcIL-18BPc. (c and d) Both FcIL-18BP fully inhibited mature IL-33-induced IL-8. (e and f) FcIL-1R4 in combination with FcIL-18BPa or FcIL-18BPc inhibited mature IL-33-induced IL-18 production and the dose response of the combined inhibitor was more linear than IL-18BP alone. The concentration of the Fc fusion inhibitor is shown at the bottom of the graph and calculated as the molar ratio. Data represent one of three independent experiments.
Figure 4 shows the characteristic biological activity of mature IL-33. (a) A precursor and mature human IL-33 was used to treat human PBMC in the presence of IL-12. The synergistic effect of human IFN gamma induction was observed in a dose dependent manner, but the high concentration of precursor IL-33 did not induce IFN gamma. (b) Similar experiments were performed with mouse spleen cells and the results were consistent with human PBMCs. The concentration of each cytokine is given at the bottom of the graph. The data represent one of five independent experiments.
Figure 5 shows that differential expression of IL-33 receptor components is cell type dependent. (a) Human HMC-1 cells were stimulated with mature IL-33 (20 ng / ml) alone or with IL-33 mixed with FcIL-1R4 (0.5 mg / ml). For antibody neutralization, mature IL-33 was added after 1 hour of pretreatment with anti-IL-1R9 (1 mg / ml) and control anti-IL-1R8. (b) Similarly, human PBMC were stimulated with mature IL-33 in the presence of IL-12. In contrast to HMC-1 cell assays, mature IL-33-induced IFNγ production was completely inhibited by anti-IL-1R9. The inhibitory activity of anti-IL-1R9 was more effective than that of FcIL-1R4, whereas the control anti-IL-1R8 did not inhibit IFNγ. Mean ± SEM **, p &lt;0.01; ***, p < 0.001 (N = 3 / group). Data represent one of three independent experiments. (c) Differential expression of IL-33 receptor components is depicted in HMC-1 and PBMC (left panel). Describes the mode of IL-33 receptor binding to its ligand (left to right panel).
Figure 6 shows the additional effect of IFNγ inhibition by IL-18 + IL-33 and IFNγ inhibition by Fc-fused IL-33R inhibition proteins. (a) IL-12 + IL-18 or IL-12 + IL-33 induced the induction of IFNγ, whereas IL-12 + IL-18 induced additional effects on IFNγ induction in the presence of IL-33. (b) IL-18BPa, IL-18BPc, and FcIL-1R4 specifically reduced IFNγ production, but FcIL-1R4 failed to inhibit IL-18-induced IFNγ (indicated by #). (c) Two or three Fc-fused IL-33R inhibitory proteins sufficiently inhibited IFNγ production compared to single inhibitors. Mean ± SEM human IFN gamma; *, p &lt;0.05; **, p &lt;0.01; ***, p < 0.001 (N = 3 / group). Data represent one of three independent experiments.
Figure 7 shows the increase of IFN gamma producing cell group by costimulatory factors. (a) human PBMCs, (b) mouse splenocytes and (c) lymphoid cells were stimulated with IL-33, LPS, IL-12, IL-12 + IL-33 or LPS + Analysis method. Intracellular staining of IL-4 and IFN gamma indicates that IL-12 + IL-33 increases the number of IFN gamma producing cells but not that of IL-4. The increased IFN gamma producing cell populations obtained by LPS were less prominent than those of IL-12 in both human and mouse cells. Data represent one of three independent experiments.
Figure 8 depicts IL-33R-associated inhibitory molecules that inhibit IFNγ induced by various costimulatory factors. (a) before stimulating human PBMCs and (b) mouse spleen cells with IL-2 + IL-33, IL-12 + IL-33, IFNa + IL-33 or TNF? + IL- FcIL-1R4 + FcIL-18BPa for 30 min at room temperature and then treated with cells. The most prominent induction of IFN [gamma] was observed in IL-12 + IL-33. IL-2 and IFNa also increased IFN [gamma] production less noticeably, but TNF [alpha] failed to produce IFN [gamma]. In the presence of several costimulatory factors, FcIL-1R4 + FcIL-18BPa effectively inhibited IL-33-induced IFNγ production Mean ± SEM human IFNγ; *, p &lt;0.05; **, p &lt;0.01; ***, p < 0.001 (N = 4 per group). Data represent one of three independent experiments.
Figure 9 is a Western blot of IL-12 + IL-33 activated signaling molecule. (a) PhosphSTAT4, NF-kB, p38MAPK, and p44 / 42MAPK were detected by stimulation of IL-2, IL-12 + IL-33, or IL-12 + IL-18 at various time points. The phosphorylation of STAT4 was observed 4 hours after stimulation and lasted up to 36 hours. Increased phosphSTAT4 persisted by IL-33 compared to IL-12 alone. PhosphNF-kB activation was detected 30 minutes after IL-12 stimulation and its activation was maintained by IL-33 and IL-18. Phosphp38 MAPK and p44 / 42 MAPK activation were not correlated with IFNγ production. The same signaling molecules were investigated with several L-33R-related inhibitory molecules. (b) At 4 hours of stimulation, only phosphNF-kB was reduced by the two combined inhibitory molecules whereas phosphSTAT4 increased at the place where FcIL-1R4 was added. (c) In 36-hour stimulation, two or three combined IL-33R-related inhibitors sufficiently inhibited phosphSTAT4, whereas single inhibitors did not. PhosphNF-kB was inhibited by all inhibitors, but Phosphp44 / 42MAPK was increased by FcIL-1R4. Stimulants and inhibitors used in the essays are listed at the top. Data represent one of three independent experiments.

The present invention will now be described in more detail by way of non-limiting examples. The following examples are intended to illustrate the invention and the scope of the invention is not to be construed as being limited by the following examples.

Example 1: IL-33 ligand-affinity chromatography

Human mature IL-33 (5 mg) was immobilized by coupling to Affigel-15 beads (1 ml volume) according to the manufacturer's instructions (Bio-Rad laboratories, Hercules, CA). One batch of 500 ml concentrated 250 ml crude urine protein was transferred to its ligand-affinity chromatography overnight at 4 ° C. The IL-33 ligand-affinity column was washed with 500 ml phosphate buffer containing 0.5 M sodium chloride, pH 8. Binding proteins were eluted in 1 ml volumes containing 25 mM citric acid, pH 2.2, and the eluted fractions were immediately neutralized with 2 M glycine.

Example 2: Western blot

For the resultant detection of IL-33 receptor-related molecules from IL-33 ligand-affinity purified water soluble proteins, 20 ml of eluted fractions were loaded on 10% SDS-PAGE. Anti-IL-18BP (YbdYbiotech, Seoul Korea), anti-IL-1R3, IL-1R4 and anti-IL-1R9 antibodies (R & D Systems, Minneapolis MN) were purchased and used for Western blot. Peroxidase-conjugated secondary antibodies (Jackson Immuno Research Laboratories, West Grove, PA) were used to develop the blots using Supex (Neuronex, Seoul Korea) and LAS-4000 imaging device (Fujifilm, Japan). Similarly, Western blots were performed with anti-IL-33 and IL-18 antibodies (YbdYbiotech).

To detect phosphorylation of signaling molecules (NF-kB, p38MAPK, and p44 / 42MAPK), human PBMC cells were stimulated with several combined cytokine stimulators in the presence or absence of IL-33 inhibitors at various time points. Cells were disrupted with kinase disruption buffer (Cell Signaling Technology, Beverly, Mass.) And subjected to 10% SDS-PAGE. The samples were transferred to a nitrocellulose membrane. The membranes were blocked in 3% BSA / TBST (Santa Cruz Biotechnology, Santa Cruz, Calif.). The membranes were first probed with anti-phosph-NF-kB, anti-phosph-p38MAPK or anti-phosph-p44 / 42MAPK (Cell Signaling Technology) and finally standardized with anti-GAPDH (Santa Cruz Biotechnology).

Example 3 Expression of Recombinant Proteins

Recombinant precursors and mature IL-33 proteins were expressed in E. coli , rosetta cells and purified with TALON affinity chromatography (Invitrogen, Carlsbad, Calif.) Using His6-tag at the N-terminus of the recombinant protein. The TALON-affinity-purified proteins were performed with high performance liquid chromatography (GE Healthcare, Waukesha, Wis.) The two-step purified recombinant proteins were purified by LAL method (Cape cod, East Falmouth, MA) (Less than 0.3 EU / mg recombinant protein) was used for the experiment.

Example 4: Cell culture and bioassay

HMC-1 cells were purchased from the American Type Culture Collection (ATCC) and maintained according to ATCC instructions. HMC-1 cells were cultured in Iscove's modified Dulbecco's medium (IMDM) suspended in 10% FBS. The bioassay was performed in 96-well plates. HMC-1 cells (10 &lt; ⁵ &gt; / ml) were seeded into each well before the assay. Several other IL-33 receptor-related inhibitors and stimulants were added to the cells. The plate was placed in a cell incubator for 18 hours and cytokines were measured in the supernatant.

Example 5: Biosease in primary human and mouse cells

Human PBMCs were separated by density centrifugation of blood in Ficoll-Paque (TM) PLUS (GE Healthcare Life Sciences, NJ, USA). PBMCs were washed twice with saline (0.9% sodium chloride) and resuspended in culture medium (RPMI 1640). Mouse spleen cells were obtained from female C57BL / 6 mice and ruptured with RBC disruption buffer (Sigma, St. Louis, Mo.) to remove erythrocytes. The cells were washed twice with culture medium (RPMI 1640) and resuspended in the same medium. PBMC (5 x 10 ⁵ ) and mouse splenocytes (1 x 10 ⁶ ) were seeded in 96-well plates in a volume of 100 ml and then cultured in 100 ml of culture medium (control) or in the presence or absence of IL-33 receptor- And then incubated with various stimulants. The costimulatory factors IL-2, IL-12 (Peprotech, Rocky Hill, NJ), IFNa2 (LG biotech, Seoul Korea) and TNFα (YbdYbiotech) were used to treat primary cells. After stimulation for 18 hours, the cell culture supernatant was used for cytokine measurement.

Example 6: Flow cytometry

Mouse spleen cells and human PBMC were obtained as above and used for flow cell analysis. For stimulation, spleen cells were cultured in 2 x 10 ⁶ cells / well of 24-well plate in 1 ml medium and incubated with IL-12 (1 ng / ml), IL-18 (20 ng / ml; YbdYbiotech), IL- / ml) and LPS (1 mg / ml; Sigma) alone or in combinations described. After 18 hour stimulation, GolgiStop (BD Bioscience, San Jose, Calif.) Was added to the cells for cytokine accumulation. After 6 hours, the cells were stained with ice for specific intracellular IFN gamma and IL-4 with specific antibodies (eBioscience, San Diego, Calif.) As described. Overall, 5 x 10 ⁴ events were collected from the FACSCalibur and analyzed using CellQuest software (BDBiosciences). PBMCs (2x10 &lt; ⁶ &gt;) were seeded into 24-well plates in a volume of 500 ml and cultured in the same manner as mouse spleen cells with various stimulants. After 24 hours of culture, the cells were stained for FACS analysis.

Example 7: Measurement of cytokine level

IL-8 and IFNγ ELISA kits were purchased from R & D systems (R & D systems). Cytokine levels were measured in the culture supernatant (100 ml) by sandwich ELISA according to the manufacturer's instructions.

The data of the present invention are expressed as means ± SEM. Statistical validity of the deviation was analyzed by unpaired, two-tailed Student's test. Values of p < 0.05 were evaluated as statistically significant.

<110> Konkuk University Industrial Cooperation Corp. <120> A novel IL-33 co-receptor and a binding protein Composition and          use of the same <160> 8 <170> Kopatentin 1.71 <210> 1 <211> 686 <212> PRT <213> Homo sapiens <400> 1 Met Lys Pro Pro Phe Leu Leu Ala Leu Val Val Cys Ser Val Val Ser   1 5 10 15 Thr Asn Leu Lys Met Val Ser Lys Arg Asn Ser Val Asp Gly Cys Ile              20 25 30 Asp Trp Ser Val Asp Leu Lys Thr Tyr Met Ala Leu Ala Gly Glu Pro          35 40 45 Val Arg Val Lys Cys Ala Leu Phe Tyr Ser Tyr Ile Arg Thr Asn Tyr      50 55 60 Ser Thr Ala Gln Ser Thr Gly Leu Arg Leu Met Trp Tyr Lys Asn Lys  65 70 75 80 Gly Asp Leu Glu Glu Pro Ile Ile Phe Ser Glu Val Arg Met Ser Lys                  85 90 95 Glu Glu Asp Ser Ile Trp Phe His Ser Ala Glu Ala Gln Asp Ser Gly             100 105 110 Phe Tyr Thr Cys Val Leu Arg Asn Ser Thr Tyr Cys Met Lys Val Ser         115 120 125 Met Ser Leu Thr Val Ala Glu Asn Glu Ser Gly Leu Cys Tyr Asn Ser     130 135 140 Arg Ile Arg Tyr Leu Glu Lys Ser Glu Val Thr Lys Arg Lys Glu Ile 145 150 155 160 Ser Cys Pro Asp Met Asp Asp Phe Lys Lys Ser Asp Gln Glu Pro Asp                 165 170 175 Val Val Trp Tyr Lys Glu Cys Lys Pro Lys Met Trp Arg Ser Ile Ile             180 185 190 Ile Gln Lys Gly Asn Ala Leu Leu Ile Gln Glu Val Gln Glu Glu Asp         195 200 205 Gly Gly Asn Tyr Thr Cys Glu Leu Lys Tyr Glu Gly Lys Leu Val Arg     210 215 220 Arg Thr Thr Glu Leu Lys Val Thr Ala Leu Leu Thr Asp Lys Pro Pro 225 230 235 240 Lys Pro Leu Phe Pro Met Glu Asn Gln Pro Ser Val Ile Asp Val Gln                 245 250 255 Leu Gly Lys Pro Leu Asn Ile Pro Cys Lys Ala Phe Phe Gly Phe Ser             260 265 270 Gly Glu Ser Gly Pro Met Ile Tyr Trp Met Lys Gly Glu Lys Phe Ile         275 280 285 Glu Glu Leu Ala Gly His Ile Arg Glu Gly Glu Ile Arg Leu Leu Lys     290 295 300 Glu His Leu Gly Glu Lys Glu Val Glu Leu Ala Leu Ile Phe Asp Ser 305 310 315 320 Val Val Glu Ala Asp Leu Ala Asn Tyr Thr Cys His Val Glu Asn Arg                 325 330 335 Asn Gly Arg Lys His Ala Ser Val Leu Leu Arg Lys Lys Asp Leu Ile             340 345 350 Tyr Lys Ile Glu Leu Ala Gly Gly Leu Gly Ala Ile Phe Leu Leu Leu         355 360 365 Val Leu Leu Val Val Ile Tyr Lys Cys Tyr Asn Ile Glu Leu Met Leu     370 375 380 Phe Tyr Arg Gln His Phe Gly Ala Asp Glu Thr Asn Asp Asp Asn Lys 385 390 395 400 Glu Tyr Asp Ala Tyr Leu Ser Tyr Thr Lys Val Asp Gln Asp Thr Leu                 405 410 415 Asp Cys Asp Asn Pro Glu Glu Glu Gln Phe Ala Leu Glu Val Leu Pro             420 425 430 Asp Val Leu Glu Lys His Tyr Gly Tyr Lys Leu Phe Ile Pro Glu Arg         435 440 445 Asp Leu Ile Pro Ser Gly Thr Tyr Met Glu Asp Leu Thr Arg Tyr Val     450 455 460 Glu Gln Ser Arg Arg Leu Ile Ile Val Leu Thr Pro Asp Tyr Ile Leu 465 470 475 480 Arg Arg Gly Trp Ser Ile Phe Glu Leu Glu Ser Arg Leu His Asn Met                 485 490 495 Leu Val Ser Gly Glu Ile Lys Val Ile Leu Ile Glu Cys Thr Glu Leu             500 505 510 Lys Gly Lys Val Asn Cys Gln Glu Val Glu Ser Leu Lys Arg Ser Ile         515 520 525 Lys Leu Leu Ser Leu Ile Lys Trp Lys Gly Ser Lys Ser Ser Lys Leu     530 535 540 Asn Ser Lys Phe Trp Lys His Leu Val Tyr Glu Met Pro Ile Lys Lys 545 550 555 560 Lys Glu Met Leu Pro Arg Cys His Val Leu Asp Ser Ala Glu Gln Gly                 565 570 575 Leu Phe Gly Glu Leu Gln Pro Ile Pro Ser Ile Ala Met Thr Ser Thr             580 585 590 Ser Ala Thr Leu Val Ser Ser Gln Ala Asp Leu Pro Glu Phe His Pro         595 600 605 Ser Asp Ser Met Gln Ile Arg His Cys Cys Arg Gly Tyr Lys His Glu     610 615 620 Ile Pro Ala Thr Thr Leu Pro Val Ser Ser Leu Gly Asn His His Thr 625 630 635 640 Tyr Cys Asn Leu Pro Leu Thr Leu Leu Asn Gly Gln Leu Pro Leu Asn                 645 650 655 Asn Thr Leu Lys Asp Thr Gln Glu Phe His Arg Asn Ser Ser Leu Leu             660 665 670 Pro Leu Ser Ser Lys Glu Leu Ser Phe Thr Ser Asp Ile Trp         675 680 685 <210> 2 <211> 590 <212> PRT <213> Artificial Sequence <220> IL-1R9-Fc <400> 2 Met Lys Pro Pro Phe Leu Leu Ala Leu Val Val Cys Ser Val Val Ser   1 5 10 15 Thr Asn Leu Lys Met Val Ser Lys Arg Asn Ser Val Asp Gly Cys Ile              20 25 30 Asp Trp Ser Val Asp Leu Lys Thr Tyr Met Ala Leu Ala Gly Glu Pro          35 40 45 Val Arg Val Lys Cys Ala Leu Phe Tyr Ser Tyr Ile Arg Thr Asn Tyr      50 55 60 Ser Thr Ala Gln Ser Thr Gly Leu Arg Leu Met Trp Tyr Lys Asn Lys  65 70 75 80 Gly Asp Leu Glu Glu Pro Ile Ile Phe Ser Glu Val Arg Met Ser Lys                  85 90 95 Glu Glu Asp Ser Ile Trp Phe His Ser Ala Glu Ala Gln Asp Ser Gly             100 105 110 Phe Tyr Thr Cys Val Leu Arg Asn Ser Thr Tyr Cys Met Lys Val Ser         115 120 125 Met Ser Leu Thr Val Ala Glu Asn Glu Ser Gly Leu Cys Tyr Asn Ser     130 135 140 Arg Ile Arg Tyr Leu Glu Lys Ser Glu Val Thr Lys Arg Lys Glu Ile 145 150 155 160 Ser Cys Pro Asp Met Asp Asp Phe Lys Lys Ser Asp Gln Glu Pro Asp                 165 170 175 Val Val Trp Tyr Lys Glu Cys Lys Pro Lys Met Trp Arg Ser Ile Ile             180 185 190 Ile Gln Lys Gly Asn Ala Leu Leu Ile Gln Glu Val Gln Glu Glu Asp         195 200 205 Gly Gly Asn Tyr Thr Cys Glu Leu Lys Tyr Glu Gly Lys Leu Val Arg     210 215 220 Arg Thr Thr Glu Leu Lys Val Thr Ala Leu Leu Thr Asp Lys Pro Pro 225 230 235 240 Lys Pro Leu Phe Pro Met Glu Asn Gln Pro Ser Val Ile Asp Val Gln                 245 250 255 Leu Gly Lys Pro Leu Asn Ile Pro Cys Lys Ala Phe Phe Gly Phe Ser             260 265 270 Gly Glu Ser Gly Pro Met Ile Tyr Trp Met Lys Gly Glu Lys Phe Ile         275 280 285 Glu Glu Leu Ala Gly His Ile Arg Glu Gly Glu Ile Arg Leu Leu Lys     290 295 300 Glu His Leu Gly Glu Lys Glu Val Glu Leu Ala Leu Ile Phe Asp Ser 305 310 315 320 Val Val Glu Ala Asp Leu Ala Asn Tyr Thr Cys His Val Glu Asn Arg                 325 330 335 Asn Gly Arg Lys His Ala Ser Val Leu Leu Arg Lys Lys Asp Leu Ile             340 345 350 Tyr Lys Ile Glu Thr Arg Glu Pro Lys Ser Cys Asp Lys Thr His Thr         355 360 365 Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe     370 375 380 Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro 385 390 395 400 Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val                 405 410 415 Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr             420 425 430 Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Val Ser         435 440 445 Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys     450 455 460 Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser 465 470 475 480 Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro                 485 490 495 Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val             500 505 510 Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly         515 520 525 Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp     530 535 540 Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp 545 550 555 560 Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His                 565 570 575 Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys             580 585 590 <210> 3 <211> 194 <212> PRT <213> Homo sapiens <400> 3 Met Thr Met Arg His Asn Trp Thr Pro Asp Leu Ser Pro Leu Trp Val   1 5 10 15 Leu Leu Leu Cys Ala His Val Val Thr Leu Leu Val Ala Thr Pro              20 25 30 Val Ser Gln Thr Thr Thr Ala Ala Thr Ala Ser Val Arg Ser Thr Lys          35 40 45 Asp Pro Cys Pro Ser Gln Pro Pro Val Phe Pro Ala Ala Lys Gln Cys      50 55 60 Pro Ala Leu Glu Val Thr Trp Pro Glu Val Glu Val Pro Leu Asn Gly  65 70 75 80 Thr Leu Ser Leu Ser Cys Val Ala Cys Ser Arg Phe Pro Asn Phe Ser                  85 90 95 Ile Leu Tyr Trp Leu Gly Asn Gly Ser Phe Ile Glu His Leu Pro Gly             100 105 110 Arg Leu Trp Glu Gly Ser Thr Ser Arg Glu Arg Gly Ser Thr Gly Thr         115 120 125 Gln Leu Cys Lys Ala Leu Val Leu Glu Gln Leu Thr Pro Ala Leu His     130 135 140 Ser Thr Asn Phe Ser Cys Val Leu Val Asp Pro Glu Gln Val Val Gln 145 150 155 160 Arg His Val Val Leu Ala Gln Leu Trp Ala Gly Leu Arg Ala Thr Leu                 165 170 175 Pro Pro Thr Gln Glu Ala Leu Pro Ser Ser His Ser Ser Pro Gln Gln             180 185 190 Gln Gly         <210> 4 <211> 428 <212> PRT <213> Artificial Sequence <220> IL-18BPa-Fc <400> 4 Met Thr Met Arg His Asn Trp Thr Pro Asp Leu Ser Pro Leu Trp Val   1 5 10 15 Leu Leu Leu Cys Ala His Val Val Thr Leu Leu Val Ala Thr Pro              20 25 30 Val Ser Gln Thr Thr Thr Ala Ala Thr Ala Ser Val Arg Ser Thr Lys          35 40 45 Asp Pro Cys Pro Ser Gln Pro Pro Val Phe Pro Ala Ala Lys Gln Cys      50 55 60 Pro Ala Leu Glu Val Thr Trp Pro Glu Val Glu Val Pro Leu Asn Gly  65 70 75 80 Thr Leu Ser Leu Ser Cys Val Ala Cys Ser Arg Phe Pro Asn Phe Ser                  85 90 95 Ile Leu Tyr Trp Leu Gly Asn Gly Ser Phe Ile Glu His Leu Pro Gly             100 105 110 Arg Leu Trp Glu Gly Ser Thr Ser Arg Glu Arg Gly Ser Thr Gly Thr         115 120 125 Gln Leu Cys Lys Ala Leu Val Leu Glu Gln Leu Thr Pro Ala Leu His     130 135 140 Ser Thr Asn Phe Ser Cys Val Leu Val Asp Pro Glu Gln Val Val Gln 145 150 155 160 Arg His Val Val Leu Ala Gln Leu Trp Ala Gly Leu Arg Ala Thr Leu                 165 170 175 Pro Pro Thr Gln Glu Ala Leu Pro Ser Ser His Ser Ser Pro Gln Gln             180 185 190 Gln Gly Thr Arg Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro         195 200 205 Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe     210 215 220 Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val 225 230 235 240 Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe                 245 250 255 Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro             260 265 270 Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr         275 280 285 Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val     290 295 300 Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala 305 310 315 320 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg                 325 330 335 Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly             340 345 350 Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro         355 360 365 Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser     370 375 380 Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln 385 390 395 400 Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His                 405 410 415 Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys             420 425 <210> 5 <211> 199 <212> PRT <213> Homo sapiens <400> 5 Met Thr Met Arg His Asn Trp Thr Pro Asp Leu Ser Pro Leu Trp Val   1 5 10 15 Leu Leu Leu Cys Ala His Val Val Thr Leu Leu Val Ala Thr Pro              20 25 30 Val Ser Gln Thr Thr Thr Ala Ala Thr Ala Ser Val Arg Ser Thr Lys          35 40 45 Asp Pro Cys Pro Ser Gln Pro Pro Val Phe Pro Ala Ala Lys Gln Cys      50 55 60 Pro Ala Leu Glu Val Thr Trp Pro Glu Val Glu Val Pro Leu Asn Gly  65 70 75 80 Thr Leu Ser Leu Ser Cys Val Ala Cys Ser Arg Phe Pro Asn Phe Ser                  85 90 95 Ile Leu Tyr Trp Leu Gly Asn Gly Ser Phe Ile Glu His Leu Pro Gly             100 105 110 Arg Leu Trp Glu Gly Ser Thr Ser Arg Glu Arg Gly Ser Thr Gly Thr         115 120 125 Gln Leu Cys Lys Ala Leu Val Leu Glu Gln Leu Thr Pro Ala Leu His     130 135 140 Ser Thr Asn Phe Ser Cys Val Leu Val Asp Pro Glu Gln Val Val Gln 145 150 155 160 Arg His Val Val Leu Ala Gln Leu Trp Val Arg Ser Ser Pro Arg Arg Gly                 165 170 175 Leu Gln Glu Glu Glu Glu Leu Cys Phe His Met Trp Gly Gly Lys Gly             180 185 190 Gly Leu Cys Gln Ser Ser Leu         195 <210> 6 <211> 433 <212> PRT <213> Artificial Sequence <220> IL-18BPc-Fc <400> 6 Met Thr Met Arg His Asn Trp Thr Pro Asp Leu Ser Pro Leu Trp Val   1 5 10 15 Leu Leu Leu Cys Ala His Val Val Thr Leu Leu Val Ala Thr Pro              20 25 30 Val Ser Gln Thr Thr Thr Ala Ala Thr Ala Ser Val Arg Ser Thr Lys          35 40 45 Asp Pro Cys Pro Ser Gln Pro Pro Val Phe Pro Ala Ala Lys Gln Cys      50 55 60 Pro Ala Leu Glu Val Thr Trp Pro Glu Val Glu Val Pro Leu Asn Gly  65 70 75 80 Thr Leu Ser Leu Ser Cys Val Ala Cys Ser Arg Phe Pro Asn Phe Ser                  85 90 95 Ile Leu Tyr Trp Leu Gly Asn Gly Ser Phe Ile Glu His Leu Pro Gly             100 105 110 Arg Leu Trp Glu Gly Ser Thr Ser Arg Glu Arg Gly Ser Thr Gly Thr         115 120 125 Gln Leu Cys Lys Ala Leu Val Leu Glu Gln Leu Thr Pro Ala Leu His     130 135 140 Ser Thr Asn Phe Ser Cys Val Leu Val Asp Pro Glu Gln Val Val Gln 145 150 155 160 Arg His Val Val Leu Ala Gln Leu Trp Val Arg Ser Ser Pro Arg Arg Gly                 165 170 175 Leu Gln Glu Glu Glu Glu Leu Cys Phe His Met Trp Gly Gly Lys Gly             180 185 190 Gly Leu Cys Gln Ser Ser Leu Thr Arg Glu Pro Lys Ser Cys Asp Lys         195 200 205 Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro     210 215 220 Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 225 230 235 240 Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Ser Glu Asp                 245 250 255 Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn             260 265 270 Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val         275 280 285 Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu     290 295 300 Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 305 310 315 320 Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr                 325 330 335 Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr             340 345 350 Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu         355 360 365 Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu     370 375 380 Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys 385 390 395 400 Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu                 405 410 415 Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly             420 425 430 Lys     <210> 7 <211> 270 <212> PRT <213> Homo sapiens <400> 7 Met Lys Pro Lys Met Lys Tyr Ser Thr Asn Lys Ile Ser Thr Ala Lys   1 5 10 15 Trp Lys Asn Thr Ala Ser Lys Ala Leu Cys Phe Lys Leu Gly Lys Ser              20 25 30 Gln Gln Lys Ala Lys Glu Val Cys Pro Met Tyr Phe Met Lys Leu Arg          35 40 45 Ser Gly Leu Met Ile Lys Lys Glu Ala Cys Tyr Phe Arg Arg Glu Thr      50 55 60 Thr Lys Arg Pro Ser Leu Lys Thr Gly Arg Lys His Lys Arg His Leu  65 70 75 80 Val Leu Ala Ala Cys Gln Gln Gln Ser Thr Val Glu Cys Phe Ala Phe                  85 90 95 Gly Ile Ser Gly Val Gln Lys Tyr Thr Arg Ala Leu His Asp Ser Ser             100 105 110 Ile Thr Gly Ile Ser Ile Ser Thu         115 120 125 Tyr Asn Asp Gln Ser Ile Thr Phe Ala Leu Glu Asp Glu Ser Tyr Glu     130 135 140 Ile Tyr Val Glu Asp Leu Lys Lys Asp Glu Lys Lys Asp Lys Val Leu 145 150 155 160 Leu Ser Tyr Tyr Glu Ser Gln His Pro Ser Asn Glu Ser Gly Asp Gly                 165 170 175 Val Asp Gly Lys Met Leu Met Val Thr Leu Ser Pro Thr Lys Asp Phe             180 185 190 Trp Leu His Ala Asn Asn Lys Glu His Ser Val Glu Leu His Lys Cys         195 200 205 Glu Lys Pro Leu Pro Asp Gln Ala Phe Phe Val Leu His Asn Met His     210 215 220 Ser Asn Cys Val Ser Phe Glu Cys Lys Thr Asp Pro Gly Val Phe Ile 225 230 235 240 Gly Val Lys Asp Asn His Leu Ala Leu Ile Lys Val Asp Ser Ser Glu                 245 250 255 Asn Leu Cys Thr Glu Asn Ile Leu Phe Lys Leu Ser Glu Thr             260 265 270 <210> 8 <211> 154 <212> PRT <213> Homo sapiens <400> 8 Ser Pro Ile Thr Glu Tyr Leu Ala Ser Leu Ser Thr Tyr Asn Asp Gln   1 5 10 15 Ser Ile Thr Phe Ala Leu Glu Asp Glu Ser Tyr Glu Ile Tyr Val Glu              20 25 30 Asp Leu Lys Lys Asp Glu Lys Lys Asp Lys Val Leu Leu Ser Tyr Tyr          35 40 45 Glu Ser Gln His Pro Ser Asn Glu Ser Gly Asp Gly Val Asp Gly Lys      50 55 60 Met Leu Met Val Thr Leu Ser Pro Thr Lys Asp Phe Trp Leu His Ala  65 70 75 80 Asn Asn Lys Glu His Ser Val Glu Leu His Lys Cys Glu Lys Pro Leu                  85 90 95 Pro Asp Gln Ala Phe Phe Val Leu His Asn Met His Ser Asn Cys Val             100 105 110 Ser Phe Glu Cys Lys Thr Asp Pro Gly Val Phe Ile Gly Val Lys Asp         115 120 125 Asn His Leu Ala Leu Ile Lys Val Asp Ser Ser Glu Asn Leu Cys Thr     130 135 140 Glu Asn Ile Leu Phe Lys Leu Ser Glu Thr 145 150

Claims (9)

Receptor and binding protein composition for interleukin (IL) -33 comprising IL-1 receptor accessory protein 2 (IL-1R9) and IL-18 binding protein (IL-18BP) as an active ingredient. The composition of claim 1, wherein said IL-1 receptor accessory protein 2 (IL-1R9) comprises one of the amino acid sequences set forth in SEQ ID NOS: 1-2. The composition of claim 1, wherein said IL-18 binding protein (IL-18BP) comprises one of the amino acid sequences set forth in SEQ ID NOS: 3-6. 5. The receptor and binding protein composition of claim 4, wherein the interleukin (IL) -33 comprises the amino acid sequence of SEQ ID NO: 7 or 8. (IL) -33 related autoimmune disease comprising at least one protein selected from the group consisting of IL-1 receptor subtype 2 (IL-1R9) and IL-18 binding protein (IL-18BP) / RTI &gt; 6. The method of claim 5, wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, osteoarthritis, chronic arthritis of childhood, Lyme arthritis, psoriatic arthritis, reactive arthritis and septic arthritis, spondyloarthritis, systemic lupus erythematosus, , Inflammatory bowel disease, insulin dependent diabetes mellitus, thyroiditis, asthma, allergic disease, psoriasis, dermatitis scleroderma, graft versus host disease, organ transplant rejection, acute or chronic immunity associated with organ transplantation, sarcoidosis, atherosclerosis, Henoch-Schonlein purpurea, microscopic vasculitis of the kidney, chronic active hepatitis, uveitis, epileptic shock, toxin shock syndrome, chronic obstructive pulmonary disease, chronic obstructive pulmonary disease, chronic obstructive pulmonary disease , Sepsis syndrome, cachexia, infectious disease, parasitic disease, acquired immunodeficiency syndrome, acute transverse myelitis, Huntington's chorea, Parkinson's disease, Alzheimer's disease, Myocardial infarction, Addison's disease, sporadic, multiple myeloid deficiency type I and multiple myeloid type II, Schmidt's syndrome, adult (acute) respiratory distress syndrome, alopecia, Arthropathy, arthropathy, arthropathy, arthritis, arthritis, arthritis, arthritis, arthritis, arthritis, arthritis, arthritis, arthritis, arthritis, arthritis, Primary free IgE, autoimmune hemolytic anemia, Coombs positive hemolytic anemia, acquired aplastic anemia, pediatric malignant anemia, myalgic encephalitis / Royal Free Disease, chronic mucosa Hepatitis B, hepatitis B virus, common variable immunodeficiency (a common mutation), autoimmune disease, autoimmune disease Interstitial fibrosing alveolitis, interstitial fibrosing alveolitis, interstitial lung disease, interstitial pneumonia, interstitial lung disease, interstitial lung disease, interstitial pneumonia, complex ovarian hyperplasia, Inflammatory bowel disease, connective tissue disease-related lung disease, systemic sclerosis-related interstitial lung disease, rheumatoid arthritis-related interstitial lung disease, systemic lupus-related lung disease, skin muscularitis / multiple myelitis related lung disease, Sjogren's disease- related lung disease, Induced autoimmune hepatitis, autoimmune hepatitis, autoimmune hepatitis, chronic autoimmune hepatitis, autoimmune hepatitis, autoimmune hepatitis, autoimmune hepatitis, autoimmune hepatitis, autoimmune hepatitis, Lupus hepatitis), type 2 autoimmune hepatitis (anti-LKM antibody hepatitis), autoimmune mediated hypoglycemia, melanosarcoma-associated type B insulin resistance, parathyroid gland Acute immune diseases related to organ transplantation, chronic immunological diseases related to organ transplantation, osteoarthritis, primary sclerosing cholangitis, psoriasis type 1, psoriasis type 2, papillary leukopenia, autoimmune neutropenia, nephrotic NOS, glomerulonephritis, Pulmonary arterial signs of pulmonary hypertension secondary to connective tissue disease, Goodpasture's syndrome, nodular polyarteritis, vasculitis, Lyme disease, discogenic lupus erythematosus, idiopathic or NOS male infertility, sperm autoimmunity, multiple sclerosis (all subtypes) , Acute rheumatic fever, rheumatic spondylitis, Stilson's disease, systemic sclerosis, Sjogren's syndrome, Takayasu's disease / arteritis, autoimmune thrombocythemia, idiopathic thrombocythemia, autoimmune thyroid disease, hypothyroidism, hypothyroid autoimmune hypothyroidism Hashimoto disease), atrophic autoimmune thyroid hypoplasia, primary mucinous edema, hydrocephalic uveitis, primary vasculitis, vitiligo, acute liver disease, chronic Induced hepatitis, non-alcoholic hepatitis, allergic and asthma, Group B streptococcus (GBS) infection, mental illness, Th2 type and Th1 type mediated diseases, liver disease, alcoholic liver cirrhosis, alcohol induced liver damage, cholestasis, (IL-33) -related autoimmune disease, characterized in that the disease is selected from the group consisting of inflammatory bowel disease, acute and chronic pain, and cancer. The method according to claim 5, wherein the IL-1 receptor subtype 2 (IL-1R9) comprises one of the amino acid sequences set forth in SEQ ID NOS: 1-2. Composition. The composition according to claim 5, wherein the IL-18 binding protein (IL-18BP) comprises one of the amino acid sequences set forth in SEQ ID NOS: 3-6. (IL) -33 associated autoimmune disease (IL-1R) comprising an antibody to at least one protein selected from the group consisting of IL-1 receptor subtype 2 (IL-1R9) and IL- Composition for prevention and treatment.

Images